References
- Druckmann R, Espié M. How can hot flushes and breast cancer be managed effectively and without risk? The 14th World Congress of the IMS; 2014 May 1–4, ; Cancun, Mexico, P178.
- Ruan X, Zhang Y, Mueck AO, et al. Increased expression of progesterone receptor membrane component1 is associated with aggressive phenotype and poor prognosis in ER positive and negative breast cancer. Menopause 2017;24:203–9.
- Neubauer H, Yang Y, Seeger H. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011;8:845–50.
- Ruan X, Neubauer H, Yang Y, et al. Progestins and membrane-initiated effects on the proliferation of human breast cancer cells. Climacteric 2012;15:467–72.
- Ruan X, Schneck H, Schultz S, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestinic effects in human breast cancer cells. Gynecol Endocrinol 2012;28:863–6.
- Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause 2013;20:504–10.
- Schneck H, Ruan X, Seeger H, et al. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells. Gynecol Endocrinol 2013;29:160–3.
- Christian Lauritzen P. Membrane-initiated effects of progestogens alone and in combination with estradiol on the proliferation of human breast cancer cells. Christian Lauritzen Award, 2011. German Menopause Society.
- Stanczyk FZ. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause 2011;18:833–4.
- Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007;105:16–36.
- Krämer E, Seeger H, Krämer B, et al. The effects of progesterone and synthetic progestogens on growth factor and estradiol treated human cancerous and non-cancerous breast cells. Menopause 2005;12:468–74.
- Winther K, Rein E, Hedman C. Femal®, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climateric 2005;8:162–70.
- Winther K, Hedman C. Assessment of the effects of the herbal remedy Femal® on the symptoms of premenstrual syndrome: a randomized, double-blind, placebo-controlled study. Curr Ther Res 2002;63:344–53.
- Gerhardsen G, Hansen AV, Killi M, et al. The efficacy of Femal® in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study. Adv Therapy 2008;25:595–607.
- Elia D, Mares P. Évaluation de la tolérance et de l’efficacité d’un complément alimentaire Sérélys® (Femal®) chez les femmes en période de ménopause[Evaluation of the tolerance and effectiveness of a Sérélys® (Femal®) dietary supplement in women during menopause]. Génésis 2008;135:12–15. French.
- Kimura H, Gruber P. Perimenopausal symptoms such as hot flushes and mood swings are reduced by a standardised pollen and pistil extracts. Poster 2008.
- D'Alterio MN, Giancane E, Cornacchia S, et al. Melis G.B GC Fem, PI 82, Vitamin E in menopause treatment: benefits for peri and postmenopausal neurovegetative symptoms. Mult J Woman`s Health 2015;4:1–6.
- Hellström AC, Muntzing J. The pollen extract femal - a nonestrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause 2012;19:825–9.
- Munoz E. Effect of a PE-F/A on estrogenic activity; Internal report Sérélys Pharma; 2012.
- Appel K. Effects of PE-F/A on the uptake of serotonin; Internal report Sérélys Pharma; 2011.